DeepLife
DeepLife is a French techbio company that builds AI-powered digital twins of human cells using multi-omics data and causal AI, serving pharmaceutical, biotechnology, and academic customers with target identification, drug repositioning, and SaaS analytics.
- Company typePrivate
- Founded2019
- HeadquartersVernon, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What DeepLife does
DeepLife is a French techbio company founded in 2019 by Jonathan Baptista (CEO) and Jean-Baptiste Morlot (CTO), headquartered in Vernon, France with additional presence in Paris. The company builds AI-powered digital twins of human cells using a Large Causal Cell Model (TwinCell) that combines multi-omics data (genomics, transcriptomics, proteomics, metabolomics), causal AI, and systems biology to simulate cellular behavior and predict drug responses. The model is trained on 1 billion harmonized single-cell multi-omics data points and a curated interactome of 15,000 proteins and 201,000 experimentally validated interactions.
DeepLife's product portfolio includes TwinCell (the core AI model and API, currently in alpha), OmicStore (a multi-omics data catalog), Cell Blueprint (a SaaS platform for cellular mechanism analysis), TwinBench (an open-source benchmarking framework), and an internal drug repositioning asset programme with two pre-clinical candidates (DL-IBD-001, an anti-fibrotic for IBD, and DL-IBD-002, an inflammatory pathway modulator for IBD and atopic dermatitis). The commercial offering combines subscription-based SaaS/API access with licensing and co-development revenue from partnership-driven drug programmes.
The company monetizes through enterprise sales to pharmaceutical and biotechnology companies, API access via the TwinCell Console, and out-licensing or co-development of drug repositioning candidates. It also operates a horizontal segmentation strategy targeting pharma, biotech, and academic research institutions, with named collaborations including Gourmey (cultivated meat), Centre Léon Bérard (oral cancer), Inserm/MIRCADE (pediatric liver cancer), and the PANC-CKI consortium (pancreatic cancer). To date DeepLife has raised approximately $16M in funding, most recently a $10M Series A in December 2024 co-led by YZR Capital and Turenne Groupe, with a team of approximately 20-25 employees across 15+ nationalities.
DeepLife firmographics
Firmographics- Name
- DeepLife
- Legal name
- DeepLife SAS
- Website
- https://deeplife.co
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DeepLife is a French techbio company that builds AI-powered digital twins of human cells using multi-omics data and causal AI, serving pharmaceutical, biotechnology, and academic customers with target identification, drug repositioning, and SaaS analytics.
- Ownership category
- akta.pro rank
DeepLife industry classification
Industry- Product category
- AI-Driven Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where DeepLife is headquartered
LocationHeadquarters
- HQ city
- Vernon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
DeepLife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- SaaS Platform (Cell Blueprint): DeepLife offers its platform as a SaaS solution, with Cell Blueprint being a key product offering. The platform enables researchers to develop precise, cost-effective therapies via cellular simulations and multi-omics analytics.
- API Access (TwinCell Console): TwinCell API providing programmatic access to the virtual cell platform for target identification and drug discovery.
- Drug Repositioning Pipeline / Asset Programme: DeepLife advances high-confidence drug candidates generated from digital twins, focusing on drug repositioning opportunities for autoimmune and neurodegenerative diseases. Revenue derived from out-licensing and co-development partnerships.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
DeepLife product offering
Product offeringCore offering
DeepLife develops AI-powered digital twins of human cells using causal AI and multi-omics data (genomics, transcriptomics, proteomics, metabolomics) to model cellular behavior and predict drug responses. Its core TwinCell platform identifies novel drug targets with mechanistic interpretability, while the Cell Blueprint SaaS product and Drug Repositioning Pipeline enable pharmaceutical and biotech customers to de-risk early-stage drug discovery and accelerate development timelines.
Product overview
DeepLife offers a platform-plus-modules architecture centered on AI-powered digital twins of human cells for drug discovery. The core offering includes TwinCell (AI-based virtual cell model for target identification), OmicStore (multi-omics data catalog with 1 billion+ data points), and Cell Blueprint (SaaS platform for cellular mechanism analysis). These products integrate through DeepLife's causal AI engine that maps cell-type-specific interactomes to identify drug targets and repositioning opportunities. The Drug Repositioning Pipeline operationalizes discoveries into clinical candidates, currently advancing DL-IBD-001 (anti-fibrotic) and DL-IBD-002 (inflammatory pathway modulator) for IBD and atopic dermatitis. The platform reduces target discovery timelines from years to months by combining causal AI, single-cell multi-omics data, and network medicine approaches.
Differentiator
Problem solved
Functional benefit
Brands
- TwinCell: AI-based Virtual Cell model for reliable and interpretable Target Identification using causal AI and digital twin technology
- OmicStore
- Cell Blueprint
- Potion
- TwinBench
- TwinCell Console
Products and services
- TwinCell An AI-based Virtual Cell model (Large Causal Cell Model) that creates interpretable digital twins of cells using causal AI to trace biological pathways and identify drug targets with traceback reasoning. Used by pharmaceutical and biotech researchers for target identification and drug discovery.
- OmicStore A curated catalog of over 1 billion harmonized single-cell multi-omics data points from public and proprietary sources, enabling cell-type-specific analysis and disease understanding. Used by researchers to access harmonized multi-omics datasets.
- Cell Blueprint A SaaS platform for decoding intricate cellular mechanisms and discovering therapeutic strategies through digital twins of cells, integrating multi-omics data with causal AI. Targeted at pharma and biotech R&D teams as a subscription-based research tool.
- Drug Repositioning Pipeline An AI-powered drug repurposing pipeline that identifies safe, FDA-approved drugs for new therapeutic uses by analyzing disease mechanisms at cellular resolution and ranking candidates using safety and novelty filters. Revenue derived from out-licensing and co-development partnerships.
- DL-IBD-001 An anti-fibrotic drug candidate undergoing pre-clinical validation for inflammatory bowel disease (IBD), assessed for safety using real-world EHR data.
- DL-IBD-002 An inflammatory pathway modulator in pre-clinical development targeting IBD and atopic dermatitis, with safety profile assessed through real-world EHR data.
- TwinBench Open-source benchmarking framework for virtual cell models that evaluates generation quality using recommendation systems and corrects for common biases like popularity bias and mode collapse.
- Avian Digital Twin World's first avian digital twin for cultivated meat optimization, integrating transcriptomics, proteomics and metabolomics data to model avian cell metabolism and regulation. Developed in partnership with Gourmey.
Quantifiable outcome
- Reduces drug development timelines by up to 40%
- +4 more outcomes
Companies that use DeepLife
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
DeepLife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
DeepLife partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, core and minor.
- Gourmey (formerly Parima)flagshipDeepLife partnered with Gourmey to develop the world's first avian digital twin for cultivated meat optimization. The collaboration combines DeepLife's biology simulation engine with Gourmey's proprietary cell cultivation platform to optimize growth conditions, nutrient density, and flavor expression. Joint research findings were published in Trends in Food Science & Technology.
- Centre Léon Bérard (CLB)coreDeepLife and Centre Léon Bérard unveiled the Oral Mucosa Cell Atlas (OMC-Atlas), mapping cellular evolution from healthy tissue to oral squamous cell carcinoma. The collaboration aims to transform early detection, biomarker discovery, and precision therapies for oral cancer.
- Inserm Transfert / MIRCADE TeamcoreDeepLife and Inserm Transfert signed a research collaboration agreement with the MIRCADE team at Bordeaux Institute of Oncology to study hepatoblastoma, the principal liver cancer in children. The SignalWise project applies generative AI to multi-omics single cell data for molecular analysis.
- COST Action INTERCEPTminorDeepLife and Centre Léon Bérard are members of the COST-funded INTERCEPT (INTercEption of oRal CancEr develoPmenT) Action working group addressing unmet oral potentially malignant disorders, developing personalized prevention and care approaches.
- PANC-CKI ConsortiumcoreLed by CasInvent Pharma, the Eurostars-funded PANC-CKI consortium secured €4 million to develop CK1 inhibitors for pancreatic cancer. DeepLife contributes AI-driven digital twins of pancreatic tumors, University of Bern provides patient-derived organoids, and AlveoliX delivers organs-on-chip platforms.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
DeepLife competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro combines machine learning with high-throughput experimental biology to build predictive models of disease. It is directly comparable to DeepLife as a techbio company using AI on biological data for drug discovery and target identification, with a similar focus on mechanistic interpretability.
- Recursion Pharmaceuticals: Recursion is a direct competitor building AI-driven digital twin biology platforms for drug discovery. Both companies share the foundational thesis of using high-dimensional biological data and AI to model cellular systems and accelerate target identification, though Recursion operates at significantly larger scale.
- Insilico Medicine: Insilico Medicine operates an AI-driven drug discovery platform spanning target identification through clinical development. DeepLife's platform-plus-asset model (with internal pipeline) closely mirrors Insilico's end-to-end approach, though with different underlying technology.
- Cellarity: Cellarity, a Flagship Pioneering company, develops medicines by targeting cellular behavior rather than single molecular targets, using AI/ML on omics data. DeepLife's cell digital twin approach mirrors Cellarity's cell-state-focused discovery paradigm.
- Exscientia: Exscientia is an AI-native pharma combining precision medicine with AI-designed drug candidates. It is comparable as an AI drug discovery platform with both partnership and proprietary pipeline elements, similar to DeepLife's hybrid business model.
Emerging players
- Cradle Bio: Cradle applies generative AI to protein design and engineering for drug discovery. It is an emerging player with partial overlap, intersecting with DeepLife where AI-driven molecular modeling meets therapeutic development.
- Bota Bio: Bota Bio is an AI-driven synthetic biology company building a biomanufacturing platform. It overlaps with DeepLife at the intersection of AI and cell engineering, though Bota focuses on industrial bio rather than pharma discovery.
Broad incumbents
- Isomorphic Labs: Isomorphic Labs, an Alphabet subsidiary, applies AI to drug discovery with a focus on biological foundations models. It is a broad incumbent in the AI drug discovery space with overlapping goals around modeling biological systems, though with substantially more capital and compute.
- Ginkgo Bioworks: Ginkgo Bioworks operates a platform for cell programming and biosecurity using synthetic biology. While broader in scope, it is comparable to DeepLife as a platform-as-a-service biology company leveraging large-scale data and engineering principles to program cellular behavior.
Regional players
- Owkin: Owkin is a French AI-biotech applying machine learning to biological and clinical data for drug discovery and development. It is a regional peer with similar European techbio DNA, though Owkin's focus on patient data and federated learning differs from DeepLife's cellular digital twin approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DeepLife social profiles
Digital presenceDeepLife financial estimates
Financial estimateRevenue estimate
Valuation estimate
DeepLife leadership team
Management profileNumber of profiles
Profiles3 records
DeepLife funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DeepLife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DeepLife
What does DeepLife do?
DeepLife develops AI-powered digital twins of human cells using causal AI and multi-omics data (genomics, transcriptomics, proteomics, metabolomics) to model cellular behavior and predict drug responses. Its core TwinCell platform identifies novel drug targets with mechanistic interpretability, while the Cell Blueprint SaaS product and Drug Repositioning Pipeline enable pharmaceutical and biotech customers to de-risk early-stage drug discovery and accelerate development timelines.
Is DeepLife a public or private company?
DeepLife is a private company. It is classified as venture growth investor backed and is currently operating.
When was DeepLife founded?
DeepLife was founded in 2019. It employs 11 to 50 people.
Where is DeepLife based?
DeepLife is headquartered in Vernon, France, in the Europe region.
How does DeepLife make money?
Three revenue lines are on record. SaaS Platform (Cell Blueprint) is the primary driver. The others are API Access (TwinCell Console) and drug Repositioning Pipeline / Asset Programme.
Who are DeepLife's main competitors?
Direct peers on record are Insitro, Recursion Pharmaceuticals, Insilico Medicine, Cellarity and Exscientia. Emerging players are Cradle Bio and Bota Bio. Broad incumbents are Isomorphic Labs and Ginkgo Bioworks. Owkin is listed as a regional player.
Does DeepLife have an API?
Yes. TwinCell API provides programmatic access to DeepLife's AI-based virtual cell model for target identification and drug discovery. Currently in alpha access with waiting list for exclusive access. The API enables developers to perform causal target identification, predict drug effects on specific cell types, and access cell-type-specific interactome analyses. Developer documentation is at twincell.deeplife.co.
What industry is DeepLife in?
DeepLife's product category is AI-Driven Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714.